Masayuki Takagi

Masayuki Takagi

Auto-generated profile, based on publicly available information

Masayuki Takagi

Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
AMAyako Maeda-Minami
Ayako Maeda-Minami
MTMasayuki Takagi
Masayuki Takagi
YMYasunari Mano
Yasunari Mano
HIHideki Ishikawa
Hideki Ishikawa
YMYutaka Matsuyama
Yutaka Matsuyama
Michihiro MutohMichihiro Mutoh
Michihiro Mutoh
Recent experimental studies have examined the efficacy of statins in preventing cancer, but the findings of clinical studies are inconsistent, and studies on Japanese patients are limited. This study aimed to clarify the association between statins and cancer risk among Japanese patients. We conducted a large population-based retrospective cohort study using the Japanese health insurance claims database, including patients newly diagnosed with dyslipidemia between 2005 and 2015. Patients who were on newly prescribed statins during the study period were designated as statin users. They were matched 1:1 with randomly selected drug nonusers who were not prescribed drugs for dyslipidemia according to age, sex, and year of first diagnosis of dyslipidemia. There were 23,746 patients in each group. The mean duration of follow-up for statin users and drug nonusers was approximately 2 years. Using a Cox proportional hazards model, significant reduction in cancer risk was observed in statin users compared with that in drug nonusers [adjusted HR = 0.84; 95% confidence interval (CI), 0.72–0.97; adjusted for patient background factors]. The results of subgroup analyses suggested that prescribed statins reduced the incidence of cancer of the digestive organs (adjusted HR = 0.79; 95% CI, 0.63–0.99) as well as reduced cancer risk in patients with nonsmokers (adjusted HR = 0.78, 95% CI = 0.65–0.92). Our results suggest that statin use may reduce cancer risk in patients with dyslipidemia. Prevention Relevance: This study clarified the relationship between statin use and cancer risk in patients with dyslipidemia. Our study will contribute to medicine selection in patients with hypercholesterolemia level. See related Spotlight, p. 1

3 April 2023
Verified
Other
Open access
AMAyako Maeda-Minami
Ayako Maeda-Minami
MTMasayuki Takagi
Masayuki Takagi
YMYasunari Mano
Yasunari Mano
HIHideki Ishikawa
Hideki Ishikawa
YMYutaka Matsuyama
Yutaka Matsuyama
Michihiro MutohMichihiro Mutoh
Michihiro Mutoh
Recent experimental studies have examined the efficacy of statins in preventing cancer, but the findings of clinical studies are inconsistent, and studies on Japanese patients are limited. This study aimed to clarify the association between statins and cancer risk among Japanese patients. We conducted a large population-based retrospective cohort study using the Japanese health insurance claims database, including patients newly diagnosed with dyslipidemia between 2005 and 2015. Patients who were on newly prescribed statins during the study period were designated as statin users. They were matched 1:1 with randomly selected drug nonusers who were not prescribed drugs for dyslipidemia according to age, sex, and year of first diagnosis of dyslipidemia. There were 23,746 patients in each group. The mean duration of follow-up for statin users and drug nonusers was approximately 2 years. Using a Cox proportional hazards model, significant reduction in cancer risk was observed in statin users compared with that in drug nonusers [adjusted HR = 0.84; 95% confidence interval (CI), 0.72–0.97; adjusted for patient background factors]. The results of subgroup analyses suggested that prescribed statins reduced the incidence of cancer of the digestive organs (adjusted HR = 0.79; 95% CI, 0.63–0.99) as well as reduced cancer risk in patients with nonsmokers (adjusted HR = 0.78, 95% CI = 0.65–0.92). Our results suggest that statin use may reduce cancer risk in patients with dyslipidemia.Prevention Relevance:This study clarified the relationship between statin use and cancer risk in patients with dyslipidemia. Our study will contribute to medicine selection in patients with hypercholesterolemia level.See related Spotlight, p. 1


3 April 2023
Verified
Other
Open access
AMAyako Maeda-Minami
Ayako Maeda-Minami
MTMasayuki Takagi
Masayuki Takagi
YMYasunari Mano
Yasunari Mano
HIHideki Ishikawa
Hideki Ishikawa
YMYutaka Matsuyama
Yutaka Matsuyama
Michihiro MutohMichihiro Mutoh
Michihiro Mutoh
Recent experimental studies have examined the efficacy of statins in preventing cancer, but the findings of clinical studies are inconsistent, and studies on Japanese patients are limited. This study aimed to clarify the association between statins and cancer risk among Japanese patients. We conducted a large population-based retrospective cohort study using the Japanese health insurance claims database, including patients newly diagnosed with dyslipidemia between 2005 and 2015. Patients who were on newly prescribed statins during the study period were designated as statin users. They were matched 1:1 with randomly selected drug nonusers who were not prescribed drugs for dyslipidemia according to age, sex, and year of first diagnosis of dyslipidemia. There were 23,746 patients in each group. The mean duration of follow-up for statin users and drug nonusers was approximately 2 years. Using a Cox proportional hazards model, significant reduction in cancer risk was observed in statin users compared with that in drug nonusers [adjusted HR = 0.84; 95% confidence interval (CI), 0.72–0.97; adjusted for patient background factors]. The results of subgroup analyses suggested that prescribed statins reduced the incidence of cancer of the digestive organs (adjusted HR = 0.79; 95% CI, 0.63–0.99) as well as reduced cancer risk in patients with nonsmokers (adjusted HR = 0.78, 95% CI = 0.65–0.92). Our results suggest that statin use may reduce cancer risk in patients with dyslipidemia.Prevention Relevance:This study clarified the relationship between statin use and cancer risk in patients with dyslipidemia. Our study will contribute to medicine selection in patients with hypercholesterolemia level.See related Spotlight, p. 1

24 November 2025
Verified
Other
Open access
AMAyako Maeda-Minami
Ayako Maeda-Minami
MTMasayuki Takagi
Masayuki Takagi
YMYasunari Mano
Yasunari Mano
HIHideki Ishikawa
Hideki Ishikawa
YMYutaka Matsuyama
Yutaka Matsuyama
Michihiro MutohMichihiro Mutoh
Michihiro Mutoh
Supplementary Figure from Association between Statins and Incidence of Cancer in Patients with Dyslipidemia Using Large-Scale Health Insurance Claims Data

3 April 2023
Verified
Other
Open access
AMAyako Maeda-Minami
Ayako Maeda-Minami
MTMasayuki Takagi
Masayuki Takagi
YMYasunari Mano
Yasunari Mano
HIHideki Ishikawa
Hideki Ishikawa
YMYutaka Matsuyama
Yutaka Matsuyama
Michihiro MutohMichihiro Mutoh
Michihiro Mutoh
Supplementary Figure from Association between Statins and Incidence of Cancer in Patients with Dyslipidemia Using Large-Scale Health Insurance Claims Data